ZIMHI®
(naloxone) Injection

 ZIMHI technology – watch our video that explains its mechanism of action

Indication

ZIMHI® (naloxone) is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. ZIMHI is intended for immediate administration as emergency therapy in settings where opioids may be present. ZIMHI is not a substitute for emergency medical care.

Important Safety Information

POTENTIAL INDICATION1 PHASE 1 PHASE 2 PHASE 3 NDA APPROVED
ZIMHI® (naloxone)2 Injection 5mg Opioid Overdose
1 Represents the next development/regulatory stage Adamis intends to pursue 2 Licensed U.S. commercial rights to US WorldMeds

As the duration of action of naloxone hydrochloride is shorter than many opioids, keep the patient under continued surveillance and administer repeated doses of naloxone using a new ZIMHI device, as necessary, while awaiting emergency medical assistance.

Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine may be incomplete. Larger or repeat doses of ZIMHI may be required.
Use in patients who are opioid dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of signs and symptoms of opioid withdrawal.

Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular (CV) effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

After use, the ZIMHI needle is exposed until the safety guard is deployed. A needlestick injury could occur during use in emergency situations. In the event of accidental needlestick injury, medical attention should be sought.
The following adverse reactions were most commonly observed in ZIMHI clinical studies: dizziness, lightheadedness, and elevated bilirubin.

To report SUSPECTED ADVERSE REACTIONS, contact Adamis Pharmaceuticals Corporation at 1-800-230-3935 or FDA at 1-800-FDA 1088 or www.fda.gov/medwatch.

Please see the full Prescribing Information and Patient Information below:

Available in pharmacies across the United States

Please visit ZIMHI.com for more information

Published ZIMHI Scientific Articles

Areas of Focus: Allergy, Respiratory and Opioid overdose

SYMJEPI® (epinephrine)

APC-400 (tempol) – Capsule